Ro.co is a telemedicine platform enabling adults to manage health from home. Patients complete online visits; US-licensed clinicians review symptoms and history, provide diagnosis, and offer personalized treatment recommendations. If a prescription is needed, Ro.co ships medications in discreet packaging with free shipping. The service emphasizes privacy and security, delivering care from online consultation to prescription delivery.
Work here?Claim your company
Industries
Company Size
1,001-5,000
Company Stage
Late Stage VC
Total Funding
$1B
Headquarters
New York City, New York
Founded
2017
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$1B
Above
Industry Average
Funded Over
6 Rounds
Eli Lilly has published results from its first clinical trial pitting retatrutide, an injectable weight-loss drug awaiting regulatory approval, against Ozempic. Patients with type 2 diabetes lost an average of 47 pounds on retatrutide, versus 21 pounds on the highest dose of Ozempic, over 16 months. Nicknamed "King Kong" or "triple G" because it mimics three hormones, the drug is seen by some as a rival to bariatric surgery. Though still in trials, knock-off versions have flooded the gray market. Separately, digital healthcare company Ro launched an AI agent called Robin. It uses data such as prescriptions and wearable readings to make health suggestions, including changes to medication doses or schedules to reduce side effects. Ro's move reflects a wider race between healthcare firms and AI giants over who can best serve patients.
Ro has launched Robin, an AI health agent meant to do more than a health query on ChatGPT. Chief executive officer and co-founder Zachariah Reitano previewed it for Business Insider, showing it handle tasks such as managing side effects, meal planning, and medication changes. Robin uses information from doctors, patient feedback, prescriptions, and smartphones to personalise recommendations. Reitano's long-term goal is to offer more care in-house and become a patient's "quarterback" for the US healthcare system, which could mean a full-service virtual clinic. Dr. Ateev Mehrotra of Brown University said it is unproven that more data yields better advice. "I would love some evidence before millions of Americans start doing this," he said, citing privacy and financial incentive concerns.
Ro Helps Patients save up to $1,200 per year on Wegovy(R) through collaboration with Novo Nordisk. The Wegovy(R) injectable and pill are now available at even lower cash pay prices on Ro March 31, 2026 - Ro, the leading direct-to-patient healthcare company, today announced that patients can save up to $1,200/year on the Wegovy(R) pen or $600/year on the Wegovy(R) pill through its collaboration with Novo Nordisk. The new savings options (including 3, 6, and 12 month prepaid plans) enable cash paying patients to access new, lower prices available for both the Wegovy(R) pen or pill. In addition, patients will soon be able to save with new, lower price Ro Body membership options. "At Ro, we fight every day to help patients achieve their health goals - but goals don't matter if treatment isn't within reach. Affordability is access, and helping patients save up to $1,200 per year on Wegovy(R) is a meaningful step toward breaking down that barrier for millions more people," said Zach Reitano, CEO and co-founder of Ro. "Working with Novo Nordisk, we're pushing forward a new model for how life-changing GLP-1 treatments reach patients - more affordably and at scale." Since April of 2025, Ro has worked with Novo Nordisk to help more patients access FDA-approved GLP-1 medications at the best available cash prices. Most recently, Ro launched Novo's new Wegovy(R) pill on its direct-to-patient platform - making the pill an option to patients nationwide on day one of its market availability. This first-of-its-kind drug launch helped meet the incredible demand for the only FDA-approved oral GLP-1 weight loss medication and make it one of the most successful launches ever. "More and more people are turning to direct-to-patient channels like Ro that seamlessly offer FDA-approved medicines and weight loss support with a convenient, end-to-end experience. By introducing new subscription pricing for Wegovy(R) at our lowest prices, we're giving people even more control over their care journey, with transparent payment options that fit their individual needs," said Ed Cinca, senior vice president, Marketing & Patient Solutions at Novo Nordisk. In April, Ro will also introduce new options offering significant savings for the Body membership, enabling patients access to high-quality ongoing care, 24/7 messaging, progress tracking and side effect monitoring, and 1-1 coaching. For those who want to check their insurance coverage, Ro's GLP-1 Insurance Checker has helped over 2 million people understand their benefits, so they can get their medication at the lowest possible price - whether that's using insurance coverage or paying cash. See Important Safety Information about GLP-1 medications, including Boxed Warning, at ro.co/safety. About ro. Ro is a direct-to-patient healthcare company with a mission of helping patients achieve their health goals by delivering the easiest, most effective care possible. Ro is the only company to offer nationwide telehealth, labs, and pharmacy services. This is enabled by Ro's vertically integrated platform that helps patients achieve their goals through a convenient, end-to-end healthcare experience spanning from diagnosis, to delivery of medication, to ongoing care. Since 2017, Ro has helped millions of patients in nearly every single county in the United States, including 99% of primary care deserts. Visit Ro.co for more information. See more news from ro. Ro Debuts First-Ever Super Bowl Commercial Starring Serena Williams to Launch "Healthier on Ro" Campaign Ro Announces Research Collaboration to Better Understand and Improve the Real-World Patient Experience with GLP-1s Ro Launches Wegovy(R) Pill Through Integration with Novo Nordisk New Research Shows Ro Helps Patients Achieve Weight Loss and Safety Outcomes Consistent with Clinical Trials Ro to Present Eight Research Abstracts at ObesityWeek 2025 Ro Collaborates with Leading Obesity Researchers to Debut New, Validated Scale to Measure 'Food Noise' Serena Williams joins Ro as GLP-1 Celebrity Ambassador Ro introduces one-month $199 Wegovy(R) new patient offer and discounted Body membership Charles Barkley partners with Ro as GLP-1 celebrity ambassador Ro integrates with NovoCare(R) Pharmacy to provide seamless access to Wegovy(R) at the lowest cash price Ro works with Lilly to streamline patient access to authentic Zepbound(R) single-dose vials by integrating with Lilly's pharmacy channel
Tennis champion Serena Williams has joined direct-to-patient healthcare company Ro as a celebrity patient ambassador for GLP-1 weight loss medications.
Patients can come to Ro for the lowest cost FDA-approved GLP-1s anywhereNEW YORK, May 22, 2025 /PRNewswire/ -- Ro today announced it is offering Novo Nordisk's first month discounted cash price of $199 for Wegovy® for new patients. Ro is able to offer this promotion immediately through its seamless integration with Novo Nordisk's direct-to-patient option NovoCare® Pharmacy
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs
Industries
Company Size
1,001-5,000
Company Stage
Late Stage VC
Total Funding
$1B
Headquarters
New York City, New York
Founded
2017
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs